Table 1.
Patient characteristics.
| Unmatched | Matched | ||||||
| Characteristics | All (%) (n = 120) | HBV group (%) (n = 43) | Non-HBV group (%) (n = 77) | P | HBV group (%) (n = 15) | Non-HBV group (%) (n = 24) | P |
| Age, y | |||||||
| ≤55 | 61 (50.8) | 31 (40.3) | 30 (69.8) | 9 (60.0) | 10 (41.7) | ||
| >55 | 59 (49.2) | 46 (59.7) | 13 (30.2) | .002 | 6 (40.0) | 14 (58.3) | .265 |
| Median (range) | 55 (17–79) | ||||||
| Sex | |||||||
| Male | 90 (75.0) | 31 (72.1) | 59 (76.6) | 8 (53.3) | 19 (79.2) | ||
| Female | 30 (25.0) | 12 (27.9) | 18 (23.4) | .583 | 7 (46.7) | 5 (20.8) | .089 |
| ECOG score | |||||||
| 0–1 | 56 (47.1) | 16 (38.1) | 40 (51.9) | 8 (53.3) | 16 (66.7) | ||
| 2–3 | 63 (52.9) | 26 (61.9) | 37 (48.1) | .148 | 7 (46.7) | 8 (33.3) | .405 |
| Primary tumor | |||||||
| Liver cancer | 36 (30.0) | 32 (74.4) | 4 (5.2) | 4 (26.7) | 4 (16.7) | ||
| Lung cancer | 27 (22.5) | 2 (4.7) | 25 (32.5) | 2 (13.3) | 5 (20.8) | ||
| Esophgeal cancer | 13 (10.8) | 1 (2.3) | 12 (15.6) | 1 (6.7) | 1 (4.2) | ||
| Melanoma | 12 (10.0) | 4 (9.3) | 8 (10.4) | 4 (26.7) | 8 (33.3) | ||
| Others∗ | 32 (26.7) | 4 (9.3) | 28 (36.4) | <.001 | 4 (26.7) | 6 (25.0) | .978 |
| Treatment modality | |||||||
| PD-1inhibitor† monotherapy | 44 (36.7) | 13 (30.2) | 31 (40.3) | 7 (46.7) | 14 (58.3) | ||
| Combination therapy‡ | 76 (63.3) | 30 (69.8) | 46 (59.7) | .274 | 8 (53.3) | 10 (41.7) | .477 |